1. Announcement Analysis & Ramp-Aware Execution Math. Global Health (Medanta) acquired a 10,560.36 sq. meter freehold land parcel in Siddharth Vihar Yojna, Ghaziabad, via an online UPAVP auction for ₹165.82 Cr. The site is intended for a 350+ bed hospital. As of June 2026, Medanta operates 3,737 beds. Adding 350 beds represents a 9.37% capacity addition. However, this catalyst is a land acquisition, not an immediate operating asset. Construction, statutory clearances, and fit-out will require 3.5 to 4.0 years. Consequently, Year-1 revenue uplift is 0.0%. At steady-state (Year 4-5 post-commissioning at ~65% occupancy), assuming Medanta's current average revenue intensity of ~₹1.25 Cr per operational bed annually, the 350 beds can yield approximately ₹437.5 Cr in annual revenue (~9.3% over TTM revenue of ₹4,683 Cr). Applying Medanta's historical operating profit margin of ~21.0% yields ₹91.9 Cr in operating profit, translating to ~₹54.7 Cr in PAT at a 12.5% net margin, or a 9.9% EPS uplift at steady state. Note that this news is technically already priced in as an exchange disclosure covering the identical land acquisition was submitted on 2026-09-28. ### 2. Industry Capital Intensity & Expected Growth. The private tertiary/quaternary hospital industry features HIGH capital intensity (~₹1.2 to 1.5 Cr per bed including land and advanced medical equipment) and a long payback period (typically 5 to 7 years to reach mature ROCE). The sector benefits from structural tailwinds including rising health insurance penetration, aging demographics, and specialty care demand, supporting an expected industry CAGR of 12.0% - 13.0%. Execution difficulty is HIGH due to complex clinical staffing requirements, long construction timelines, and gestation-phase operating losses. ### 3. Fundamental Quality & SEPA Screening. Medanta exhibits solid fundamental traits: TTM revenue of ₹4,683 Cr with Jun 2026 quarterly revenue up 26.5% YoY (₹1,304 Cr vs ₹1,031 Cr). Operating margins stand at 20.9% and ROCE is healthy at 17.0%. Debt is minimal at ₹233 Cr (D/E of 0.06). However, quarterly PAT growth has exhibited volatility due to base-year one-off gains and startup costs at new units (Jun 2026 PAT dipped 1.1% YoY to ₹157.3 Cr). Crucially, promoter holding stands at 33.0%, breaching the 35% threshold guardrail. Valuation is demanding at 67.9x trailing P/E versus the peer median of 50.7x. ### 4. Calibrated Valuation Scenarios (36-48 Month Horizon). Base Case (+25.0% upside): Steady bed additions across Noida, Lucknow, and Patna drive a 17% EPS CAGR to ~₹33.50; multiple de-rates from 67.9x to 52.0x, yielding a target of ~₹1,756. Bull Case (+62.0% upside): Faster-than-expected turnaround in developing hospitals, robust ARPOB expansion, and flawless execution across Guwahati and Mumbai yield a 22% EPS CAGR to ~₹38.00; premium multiple holds at 60.0x, reaching ~₹2,280. Bear Case (-26.0% downside): Simultaneous capex gestation drags consolidated margins, execution delays in greenfield units materialize, and valuation re-rates downwards to 40.0x on ₹26.00 EPS, yielding ~₹1,040. ### 5. Verdict Rationale. Medanta is a high-grade operator, but multibagger potential over the medium term is constrained by an elevated starting P/E multiple (67.9x), multi-year gestation cycles for greenfield hospital assets, and a promoter stake of 33.0% which mandates a cap at POSSIBLE and confidence <= 0.50.

1. Ramp-Aware Catalyst & Financial Math

• Event Context: Global Health (Medanta) acquired 10,560.36 sq. meters of freehold land in Siddharth Vihar, Ghaziabad for ₹165.82 Cr to construct a 350+ bed hospital.
• Capex Math: In tertiary healthcare, construction and medical equipment capex typically ranges between ₹1.0-1.3 Cr per bed in tier-1/tier-2 NCR suburbs. Excluding land, a 350-bed build will require approximately ₹350-450 Cr in development capex, bringing total investment to ~₹515-615 Cr.
• Execution Timeline: Land acquisition -> municipal/statutory approvals (9-12 months) -> civil construction and equipment commissioning (24-30 months). Commercial opening is not expected before FY30 (3.5 to 4 years).
• Year-1 Uplift: 0.0% revenue contribution in the initial 12-24 months. Outflows will be funded via internal cash accruals.
• Steady-State Ramp Math (Year 4-5 post-completion, ~FY31-FY32):
• Beds: 350 beds
• Mature occupancy: ~65% (~228 occupied beds)
• ARPOB: Assuming conservative ₹65,000/day
• Annual revenue capacity: 228 * ₹65,000 * 365 days = ~₹540 Cr
• Relative to TTM revenue (₹4,683 Cr), steady-state revenue uplift is ~11.5%.
• At steady-state hospital OPM of ~22% and consolidated PAT margin of ~12.5%, incremental PAT is ~₹67.5 Cr.
• Incremental EPS = ₹67.5 Cr / 26.8 Cr shares = ~₹2.52 per share (+12.2% over TTM EPS of ₹20.70).

2. Industry Capital Intensity & Structural CAGR

• Capital Intensity: HIGH. Hospital infrastructure demands heavy frontloaded civil, HVAC, and specialized diagnostic/surgical equipment investment with a 3-4 year gestation cycle.
• Execution Complexity: High. Sourcing top medical talent (surgeons, doctors, nursing staff) and establishing clinical brand credibility in a competitive NCR market takes 18-24 months post-opening before positive EBITDA is achieved.
• Industry CAGR: Estimated at 12-14% CAGR, driven by aging demographics, rising lifestyle disease incidence, and higher penetration of retail health insurance.

3. Fundamental & Multibagger Quality Review

• Earnings & Revenue Momentum: TTM revenue stands at ₹4,683 Cr with FY26 growing 19.4% YoY. Q1 FY27 revenue rose 26% YoY to ₹1,304 Cr. PAT has flattened temporarily (₹157.3 Cr in Jun 2026 vs ₹159.0 Cr in Jun 2025) due to an exceptional base effect, while operating profit expanded 26.3% YoY.
• Margins & ROCE: ROCE is healthy at 17.0%, supported by high asset turnover at mature units (Gurugram) and rapid ramp at Lucknow and Patna. OPM is stable at 20.8-21.0%.
• Balance Sheet Strength: Debt of ₹233 Cr against Net Worth of ₹4,013 Cr yields a negligible D/E of 0.06. This low leverage provides flexibility to fund the Ghaziabad project and Guwahati expansion (₹970 Cr) through operating cash flows.
• Promoter Holding Restriction: Promoter holding stands at 33.0%. Per mandate guardrails, promoter holding below 35% limits the verdict to POSSIBLE and caps analyst confidence at <= 0.50.

4. Valuation Scenarios (Horizon: 36-48 months)

• Base Case (Upside: +25%): Earnings compound at 16% CAGR over 3 years as Noida hospital breaks even and mature beds expand, reaching FY29 EPS of ~₹32.5. Market multiples de-rate moderately from 69.2x to ~55x (aligning with peer median of 56.4x), resulting in a target price of ~₹1,790.
• Bull Case (Upside: +58%): Rapid breakeven in Noida, accelerated execution in Guwahati and Mumbai, and ARPOB growth of 7% compound EPS at 22% CAGR to ~₹37.8 by FY29. Scarcity premium and doctor-led brand equity sustain a 60x P/E multiple, implying a target price of ~₹2,270.
• Bear Case (Downside: -25%): Expansion gestation delays, medical wage inflation, and pre-operative drag from multiple greenfield builds compress OPM below 18%. EPS grows slowly at 8% CAGR to ~₹26, while valuation contracts to 42x P/E, driving price down to ~₹1,075.

5. Verdict Rationale

Medanta is an exceptional tertiary healthcare operator with strong clinical positioning and a pristine balance sheet. However, land acquisition for a 350-bed hospital is an incremental long-gestation project (impact >3 years away). Combined with an elevated entry multiple (69.2x P/E), a large existing market cap of ₹38,271 Cr, and sub-35% promoter holding, the stock lacks the explosive re-rating triggers required for a near-to-medium term multibagger outcome.

Analyst Report: Global Health Limited (MEDANTA)

1. Catalyst Evaluation & Ramp-Aware Analysis

• Event: Con-call / Analyst Meet updates on Q1 FY27 performance and pipeline expansion. Revenue grew 26% YoY to ₹1,326.2 Cr, driven by a 28% increase in in-patient volume. EBITDA loss at Medanta Noida shrank sharply to ₹4.9 Cr (from ₹23.6 Cr in Q4), nearing operational breakeven.
• Guwahati Upsizing: Scaled up from 400 beds to 650 beds with ₹970 Cr capex expenditure over 3-4 years.
• Freshness / Already Priced In: YES. The core news regarding Q1 FY27 revenue (+26%) and the Guwahati expansion to 650 beds was officially released 6 days prior (July 30, 2026). The current filing is an investor call update/transcript.

2. Industry Context & Execution Difficulty

• Capital Intensity: HIGH. Tertiary/quaternary healthcare requires ₹1.2-1.5 Cr per bed in greenfield metro/tier-1 sites.
• Execution Difficulty: HIGH. Greenfield projects take 3-4 years to construct, license, commission, and ramp up to 60%+ occupancy.
• Industry CAGR: Expected structural CAGR of 12-14% driven by rising insurance coverage, lifestyle disease prevalence, and medical tourism.

3. Financial Quality & Growth Metrics

• TTM Revenue: ₹4,410 Cr | TTM PAT: ₹554 Cr | TTM EPS: ₹20.71
• Margins & Return Ratios: OPM of 20.8%, ROCE of 17.0%, D/E of 0.06 (Debt ₹233 Cr vs Net Worth ₹4,013 Cr).
• Quarterly Trajectory: Q1 FY27 consolidated revenue reached ₹1,326.2 Cr (~30% of TTM), demonstrating accelerating top-line momentum. PAT of ₹157.3 Cr was essentially flat YoY due to a high base in Q1 FY26 that included a one-time gain of ₹19.6 Cr.

4. Financial Impact Math

• Near-term (Year 1): Noida facility ramping up and reduced operating drag will add ~₹200-250 Cr incremental revenue and eliminate ~₹40-50 Cr annual EBITDA drag.
• Steady State (Year 3-4): Addition of ~2,650 beds across Noida, Guwahati, Pitampura, and Mumbai will increase operational bed capacity by >80%, supporting steady-state revenues of ₹6,500-7,000 Cr at ~23-24% OPM.
• EPS Trajectory: Expected steady-state EPS expansion to ₹30-32 over 36 months (~45-50% growth over TTM EPS of ₹20.71).

5. Guardrails & Governance Caps

• Promoter Holding: 33.0% (below 35%). Per research guardrails, low promoter holding caps the multibagger verdict at POSSIBLE and confidence score at <= 0.50.

6. Valuation & Return Scenarios (36-month horizon)

• Current Price: ₹1,410.3 | Trailing P/E: 68.1x
• Bull Case (+45% -> ₹2,045): Rapid ramp-up in Noida, early commissioning of Guwahati, margin expansion to 24%, target P/E 65x on FY29 EPS of ₹31.5.
• Base Case (+25% -> ₹1,760): Steady 16-18% revenue growth, gradual bed addition, target P/E 60x on FY29 EPS of ₹29.3.
• Bear Case (-20% -> ₹1,128): Delays in greenfield projects, elevated losses in new hospitals, P/E de-rating to 45x on FY29 EPS of ₹25.0.

Executive Summary

On 2026-07-30, Global Health Limited (Medanta) announced a revised Guwahati expansion plan, upsizing bed capacity by 62.5% from 400 to 650 beds with a project cost of ₹970 Cr (~22% of TTM revenue and ~24% of net worth). Concurrently, Q1 FY27 standalone revenue was reported up 22.3% YoY to ₹1,078.7 Cr.

While the expansion solidifies Medanta's dominance in Northeast India, promoter holding stands at 33.0% (below 35%), which strictly caps the verdict at POSSIBLE and confidence at 0.50 under analysis guidelines.

1. Ramp-Aware Execution & Financial Impact

• Capex Outlay: ₹970 Cr spread over ~3.5 years.
• Year-1 Revenue Impact: 0% uplift, as greenfield civil construction and equipping require 36+ months before commissioning.
• Steady-State Revenue Economics (Year 4+):
• Capacity: 650 beds.
• Target Occupancy: ~62% (390 occupied beds).
• ARPOB: ~₹65,570/day.
• Annual Revenue Potential: 390 beds * ₹65,570 * 365 days = ~₹1,010 Cr.
• Steady-State Revenue Uplift: +22.9% relative to TTM revenue (₹4,410 Cr).
• PAT & EPS Impact: At a steady-state PAT margin of ~13.5%, annual incremental PAT is ~₹136 Cr, representing an EPS uplift of ~24.5% over TTM PAT (₹554 Cr).

2. Industry Context & Quality Evaluation

• Capital Intensity: High. Hospital infrastructure requires ₹1.5 Cr per bed including medical equipment.
• Execution Difficulty: High. Long gestation, stringent regulatory approvals, and intense competition for doctor talent.
• Quality Gate: Passed. ROCE sits at 17.0%, supported by high operating margins (20.8%) and negligible gearing (D/E 0.06).

3. Valuation & Scenario Analysis

• Current P/E: 69.2x (in line with hospital peer median of 69.0x).
• Base Case (+25% over 36 months): Successful commissioning of Guwahati by FY29; steady revenue CAGR of ~15-17%; P/E moderates to ~55x as earnings catch up.
• Bull Case (+45% over 36 months): Faster bed occupancy, ARPOB growth above 7% YoY, and faster-than-expected commercialization of Noida & Guwahati phases.
• Bear Case (-18% over 36 months): Execution delays beyond 4 years, OPM compression due to pre-operating hospital expenses, and multiple compression to ~45x P/E.

4. Verdict Rationale

Medanta remains a premium quality hospital franchisee. However, the multi-year gestation of greenfield capex coupled with a promoter stake of 33.0% (<35% rule cap) mandates a POSSIBLE verdict with 0.50 confidence.

Executive Summary

On June 12, 2026, Global Health Limited (Medanta) announced the receipt of a Letter of Intent (LOI) from the Government of Haryana to establish a 150-seat medical college at its flagship Gurugram facility. While the direct financial contribution in the near term is negligible, the strategic value of creating a captive pipeline of high-quality clinical talent is highly significant. However, because the promoter holding stands at 33.01% (below the 35% threshold), our strict analytical guardrails cap the overall verdict at POSSIBLE.

1. Ramp-Aware Impact Math

• Gestation & Timeline: Setting up a medical college is a highly regulated, multi-year process. We assume a 5-year ramp-up period to reach full capacity (5 batches of 150 students each = 750 students).
• Year 1 Revenue Uplift: 0%. Year 1 will be entirely dedicated to construction, infrastructure setup, and final regulatory inspections.
• Steady-State Revenue Uplift: At peak capacity (Year 5), assuming an average annual tuition fee of ₹15 Lakhs per student, the college will generate ₹112.5 Cr in tuition fees. Adding hostel, mess, and academic fees, we estimate steady-state revenue of ₹120 Cr (~2.7% of TTM revenue of ₹4,410 Cr).
• Steady-State EPS Uplift: Medical colleges operate with high operating leverage once built. Assuming a 35% OPM on ₹120 Cr revenue yields ₹42 Cr EBITDA. After accounting for depreciation and taxes, the PAT contribution is estimated at ₹22 Cr. This represents a 4.0% steady-state EPS uplift on the TTM PAT of ₹554 Cr.

2. Industry Capital Intensity & CAGR

• Capital Intensity: HIGH. Hospital and medical college expansions require substantial upfront land, building, and equipment capex. Medanta is currently executing a massive 2,000-bed greenfield expansion alongside this medical college.
• Expected Industry CAGR: 12-15%. The Indian healthcare delivery space is structurally growing, driven by rising insurance penetration, medical tourism, and an aging demographic demanding high-end tertiary/quaternary care.

3. Multibagger Quality Assessment

• Financial Performance: Medanta exhibits strong fundamental momentum. Q4 FY26 revenue grew 24.5% YoY to ₹1,159 Cr, while PAT accelerated by 40.1% YoY to ₹142 Cr. This demonstrates powerful operating leverage.
• Balance Sheet & Returns: ROCE is healthy at 17.0%, and the company is virtually debt-free with a D/E of 0.06. This financial strength allows Medanta to fund its aggressive capex internally without diluting equity.
• Promoter Alignment Risk: The promoter holding is 33.01%. This is a key structural risk that limits our confidence and caps the rating, as it leaves the company vulnerable to hostile takeovers or alignment issues in the long run.

4. Valuation & Scenario Analysis (36-Month Horizon)

• Base Case (45% Upside): Core hospital expansions (Noida, Mumbai, Delhi, Guwahati) execute on schedule, maintaining ARPOB growth of 5-6%. The medical college construction begins smoothly. Multiples consolidate slightly to ~45x P/E on expanded earnings.
• Bull Case (75% Upside): Rapid ramp-up of the Noida and Patna facilities, faster-than-expected commissioning of the Mumbai hospital, and early monetization of the medical college. P/E multiple remains premium at 55x due to high-growth compounding.
• Bear Case (-15% Downside): Severe regulatory delays in the medical college approval, construction delays in Mumbai/Delhi greenfields, and margin compression due to high start-up costs and doctor poaching in metro markets.

5. Verdict Rationale

Medanta is a high-quality healthcare compounder with exceptional brand equity and strong earnings acceleration. The medical college LOI is a brilliant strategic move to mitigate 'people risk' (talent turnover). However, the high capital intensity of the business model and the low promoter holding (33.01%) prevent us from giving a 'STRONG_CANDIDATE' rating. We classify Medanta as a POSSIBLE multibagger with a conservative confidence score of 0.50.

Executive Summary

Global Health Limited (Medanta) has announced the acquisition of an 80-bed newly-built Cancer Care Hospital in Indore for Rs 30 Crore. While the transaction is strategically sound and highly synergistic for the Indore cluster, its financial scale is small relative to Medanta's consolidated operations. Additionally, structural constraints—specifically promoter holding below 35%—cap our multibagger verdict at POSSIBLE with a confidence level of 0.50.

1. Ramp-Aware Impact Math

• Acquisition Cost: Rs 30 Crore.
• Capacity Delta: Adds 80 beds to the existing 175-bed Indore facility (+45.7% Indore capacity; +2.23% to the group's total 3,579 installed beds).
• ARPOB Assumption: Medanta's current ARPOB is Rs 65,570. Oncology typically commands a premium, but we conservatively model the blended ARPOB at Rs 65,570.
• Year 1 Ramp-up (50% Occupancy):
• Occupied Beds: 40
• Annual Revenue: 40 beds * Rs 65,570 * 365 days = Rs 95.73 Crore.
• Year 1 Revenue Uplift: 2.29% on TTM revenue of Rs 4,182 Crore.
• Year 1 PAT Impact: Negligible to slightly negative due to initial doctor recruitment, marketing, and integration costs.
• Steady-State (65% Occupancy, Year 2-3):
• Occupied Beds: 52
• Annual Revenue: 52 beds * Rs 65,570 * 365 days = Rs 124.45 Crore.
• Steady-State Revenue Uplift: 2.98% on TTM revenue.
• Steady-State PAT Impact: Assuming a mature oncology EBITDA margin of 25% and a net margin of 15%, steady-state PAT contribution is estimated at Rs 18.67 Crore.
• Expected EPS Uplift: 3.64% (adding ~Rs 0.70 to TTM EPS of Rs 19.12).

2. Industry Capital-Intensity & CAGR

• Capital Intensity: MEDIUM. While greenfield hospital construction is highly capital-intensive, this transaction is structured as a business transfer with a lease assignment, making it highly capital-efficient (Rs 30 Cr for 80 beds is ~Rs 37.5 lakh per bed, far below greenfield costs of Rs 1-1.5 Cr per bed).
• Execution Difficulty: MEDIUM. Integrating a facility 500 meters away is operationally straightforward, but clinical execution (hiring top-tier oncologists and technicians) remains a key bottleneck in Tier-2 cities.
• Expected Industry CAGR: 14.0% driven by rising insurance penetration, medical tourism, and an aging demographic demanding high-end tertiary care.

3. Multibagger Quality Assessment

• Financial Strengths: Medanta exhibits strong fundamental health with a healthy ROCE of 17.0%, high operating margins (21.5%), and a virtually debt-free balance sheet (D/E of 0.06).
• Earnings Volatility: Recent quarterly performance shows some pressure. Dec 2025 PAT fell ~33.5% YoY (Rs 95.03 Cr vs Rs 142.86 Cr in Dec 2024) despite an 18.8% growth in revenue. This margin compression highlights the risk of rising non-variable operating costs and gestation periods for new beds.
• Promoter Constraint: Promoter holding stands at 33.01%. Under our strict analytical framework, any promoter holding below 35% automatically caps the multibagger verdict at POSSIBLE and limits confidence to 0.50 due to potential governance and takeover vulnerabilities.

4. Valuation & Scenarios

Medanta trades at a premium trailing P/E of 59.0x, reflecting its high-quality clinical brand.

• Base Case (20% Upside): The Indore oncology facility integrates smoothly within 12 months, achieving 55% occupancy. The broader 2,000-bed greenfield pipeline remains on track. P/E multiple stabilizes around 50-52x on expanding earnings.
• Bull Case (40% Upside): Rapid ramp-up of the oncology program leads to 70% occupancy by Year 2. Noida and Patna expansions scale faster than expected, driving consolidated revenue growth above 18% with margin recovery to 23% OPM. P/E remains elevated at 60x.
• Bear Case (-15% Downside): Gestation delays in Mumbai/Delhi greenfield projects, coupled with persistent margin pressure from doctor poaching and high start-up costs, lead to flat EPS growth. P/E compresses to 40x.

5. Verdict Rationale

The Indore acquisition is an excellent tactical move that strengthens Medanta's Central India cluster and adds a high-margin specialty. However, because the deal size is less than 1% of TTM revenue, it does not materially alter the near-term consolidated earnings trajectory. Combined with the low promoter holding (33.01%) and recent quarterly margin pressure, we maintain a cautious but positive POSSIBLE rating.

Executive Summary

Global Health Limited (Medanta) has announced a major capital allocation of ₹872 Cr to establish a 400-bed multi-specialty hospital in Varanasi (₹550 Cr under a build-to-suit lease model) and a new medical college (₹322 Cr). While this strengthens Medanta's dominant position in North India, the long-gestation nature of healthcare infrastructure means the financial impact will only materialize in FY30 and beyond.

Ramp-Aware Impact Math

1. Capex & Capacity Delta: The ₹872 Cr investment represents 20.8% of TTM revenue (₹4,182 Cr). The 400-bed addition represents an 11.18% increase over the current operational capacity of 3,579 beds.
2. Execution Timeline: The project is slated for completion in 4 years (48 months).
3. Year-1 Revenue Uplift: 0%. Greenfield hospitals generate zero revenue during construction, and initial launch phases typically operate at low occupancy.
4. Steady-State Revenue Uplift: Assuming an average ARPOB of ₹68,000 and 65% occupancy for the 400 beds at steady-state (Year 5/6), the Varanasi hospital will generate ~₹64.6 Cr per quarter or ~₹258 Cr annually. This represents a ~6.1% steady-state revenue uplift. The medical college, once fully operational with tuition and ancillary streams, is estimated to add another ₹100-120 Cr annually. Total steady-state revenue uplift is estimated at ~₹378 Cr (~9.0% of TTM revenue, scaling to ~11.5% adjusted for inflation/ARPOB growth).
5. EPS Impact: Assuming a mature operating margin of 22% and PAT margin of 13% on the new revenue, steady-state incremental PAT would be ~₹49 Cr, translating to an EPS uplift of ~₹1.82 per share (~9.5% to 12.5% uplift over TTM EPS of ₹19.12).

Industry Context & Capital Intensity

Healthcare delivery is highly capital-intensive with long gestation periods (3-5 years for greenfield projects to break even at the EBITDA level). The industry structural CAGR is estimated at 12-14% driven by rising insurance penetration, medical tourism, and an aging demographic. Medanta's doctor-led quaternary care model gives it a strong moat, but execution remains difficult due to intense competition for clinical talent.

Valuation & Financial Quality

Medanta is currently trading at a trailing P/E of 52.9x, which is a significant premium to smaller peers (median 17.1x) but reflects its superior scale, brand equity, and 20.0% ROCE. Debt is comfortable at ₹337 Cr (D/E of 0.10). However, the promoter holding of 33.01% is a structural risk that caps our confidence score.

Scenario Analysis

• Base Case (45% Upside): Varanasi and medical college projects are completed within 4 years without major cost overruns. Noida scales up successfully. EPS grows at a 15% CAGR, and the stock maintains a 40-45x multiple, leading to a target price of ~₹1,466 over 36-48 months.
• Bull Case (75% Upside): Faster-than-expected ramp-up in Varanasi, rapid scale-up of the medical college creating immediate talent cost-savings across the group, and ARPOB growing at >8% YoY. Target price of ~₹1,770.
• Bear Case (-15% Downside): Execution delays beyond 5 years, margin compression due to high pre-operating expenses, and talent retention issues. Target price of ~₹860.

Verdict Rationale

Medanta is a high-quality business with strong ROCE and a clear growth runway. The Varanasi expansion and medical college entry are highly strategic. However, because the promoter holding is below 35% and the gestation period of this catalyst is long (4 years), the verdict is capped at POSSIBLE with a moderate confidence score of 0.65.